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intake, (ii) periconceptional supplementation, (iii) flour forti-
fication, and (iv) the recent attempt for the use of combina-
tion of oral contraceptives with 6S-5-methytetrahydrofolate 
(methylfolate), are discussed. Obviously, prevention of NTD is 
much better than the frequent elective termination of preg-
nancies after prenatal diagnosis of NTD fetuses. 
 Copyright © 2011 S. Karger AG, Basel 
 
Structural birth defects, i.e. congenital abnormalities 
(CAs), represent a special category of human disorders 
due to their very early onset and defect condition; there-
fore there is a limited chance for the complete recovery of 
CAs. Thus there is only one optimal approach to CAs in 
medical practice and it is their prevention.
 Neural-tube defects (NTD) are the most frequent and 
the most tragic CAs of the central nervous system. For-
tunately, there was a breakthrough in the prevention of 
NTD during the 1980s and 1990s via periconceptional 
folic acid or folic acid-containing multivitamins.
 History 
 The occurrence of NTD, i.e. anencephaly and spina 
bifida,  depends on the maternal socioeconomic status 
(low risk in the highest class to above-average risk in the 
lowest class); thus Smithells et al.  [1] hypothesized that 
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 Abstract 
 Background/Aims: To review the main results of interven-
tion trials which showed the efficacy of periconceptional folic 
acid-containing multivitamin and folic acid supplementation 
in the prevention of neural-tube defects (NTD).  Methods and 
Results: The main findings of 5 intervention trials are known: 
(i) the efficacy of a multivitamin containing 0.36 mg folic acid 
in a UK nonrandomized controlled trial resulted in an 83–91% 
reduction in NTD recurrence, while the results of the Hungar-
ian (ii) randomized controlled trial and (iii) cohort-controlled 
trial using a multivitamin containing 0.8 mg folic acid showed 
93 and 89% reductions in the first occurrence of NTD, respec-
tively. On the other hand, (iv) another multicenter random-
ized controlled trial proved a 71% efficacy of 4 mg folic acid 
in the reduction of recurrent NTD, while (v) a public health-
oriented Chinese-US trial showed a 41–79% reduction in the 
first occurrence of NTD depending on the incidence of NTD. 
 Conclusions: Translational application of these findings 
could result in a breakthrough in the primary prevention of 
NTD, but so far this is not widely applied in practice. The ben-
efits and drawbacks of 4 main possible uses of periconcep-
tional folic acid/multivitamin supplementation, i.e. (i) dietary 
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undernutrition could be the common factor in the origin 
of NTD. His group tested the effect of diet supplemented 
with a multivitamin containing 0.36 mg folic acid in the 
first intervention trial. Women who had had one or more 
previous infants with NTD were supplemented by this 
multivitamin during the periconceptional period while 
controls were recruited among similar women who were 
already pregnant without vitamin supplementation. The 
results of this intervention study were published sepa-
rately for the Yorkshire region of the UK  [1]  and Northern 
Ireland  [2] ,  and they found 91 and 83% reductions in 
NTD recurrence, respectively.
 However, their results were not accepted by some ex-
perts because of possible selection bias in their non-ran-
domized controlled trial (RCT). Thus the Medical Re-
search Council (MRC) in the UK organized a multicenter 
RCT (43% of the participants came from Hungary). There 
were 4 supplementation groups: folic acid (4 mg), other 
vitamins, folic acid + other vitamins, and minerals as the 
control. The MRC Vitamin Study found that a pharma-
cological dose (4 mg) of folic acid alone can reduce NTD 
recurrence by 71% (0.8 vs. 4.3%; RR 0.29; 95% CI 0.12–
0.71)  [3] .
 Periconceptional multivitamin supplementation was 
incorporated into the Hungarian Periconception Service 
(HPS) launched in 1984  [4] as an RCT. Half of the par-
ticipants were supplied a micronutrient combination 
(the so-called ‘multivitamin’ contained 12 vitamins, 
among them folic acid 0.8 mg, B 12 4.0   g, B 6 2.6 mg, and 
B 2  1.8 mg, 4 minerals, and 3 trace elements), while the 
other half of the participants were supplied a placebo-
like trace element combination, i.e. ‘no multivitamin’, 
randomly. These women used the supplements at least 
for 1 month before conception and at least for 2 months 
after conception because the critical period of anenceph-
aly is between the 35th and 40th gestational days, while 
spina bifida had this period between the 37th and 42nd 
gestational days.
 There were 2 major questions regarding the Hungar-
ian RCT following the publications of the above two ‘re-
currence’ studies: (i) Do folic acid-containing multivita-
mins reduce the risk of the first occurrence of NTD? 
About 95% of women who have a fetus or infant with 
NTD had no previous NTD pregnancies; thus the preven-
tion of their first occurrence would be a real public health 
success. (ii) The pharmacological dose (4 mg) of folic acid 
used in the MRC Vitamin Study might have some adverse 
effects; thus an objective was to evaluate the physiological 
dose (1 mg or less) of folic acid. The trial tested the effi-
cacy of a multivitamin containing 0.8 mg folic acid.
 NTD did not occur in 2,391 offspring of the multivi-
tamin group, while 6 NTD were found in 2,471 offspring 
of the no-multivitamin group (p = 0.01; RR 0.07; 95% CI 
0.01–0.13). Thus, the Hungarian RCT demonstrated first 
that a multivitamin containing 0.8 mg folic acid prevent-
ed at least 90% of the first occurrences of NTD  [5] .
 For ethical reasons, the Hungarian RCT could not be 
continued; thus a cohort-controlled trial (CCT) was de-
signed to collect more data regarding the preventive ef-
fect of this multivitamin for NTD and other CAs. All par-
ticipants in the HPS were supplied the multivitamin used 
in RCT, while women for the unsupplemented cohort 
were recruited in the 14th week of pregnancy without vi-
tamin use from the regional prenatal care clinics and they 
were matched to each pregnant woman of the supple-
mented cohort. The protective effect of this multivitamin 
for the reduction of NTD was confirmed in these 3,056 
‘pairs’ (1 vs. 9; OR 0.11; 95% CI 0.01–0.91)  [6] .
 These Hungarian intervention trials showed the effi-
cacy of this multivitamin in the reduction of some other 
CAs, and mainly cardiovascular CAs, but these data are 
not discussed here.
 Later, the efficacy of 0.4 mg folic acid for the preven-
tion of the first occurrence of NTD was shown in a Chi-
nese-US study  [7] . There was a 79% reduction in the risk 
of NTD in areas with high rates of NTD (6.5 per 1,000), 
while this reduction was 41% in areas with low rates of 
NTD (0.8 per 1,000).
 Many observational studies of folic acid-containing 
multivitamins or folic acid alone were also published, 
which confirmed the prevention of NTD, but only the 
data of intervention trials were summarized above.
 Hyperhomocysteinemia-Related NTD 
 The origin of NTD can be explained by the interaction 
of genes and environmental factors (such as dietary defi-
ciency). Several genetic and environmental factors con-
tribute to the origin of NTD; here only the most estab-
lished one, i.e. hyperhomocysteinemia, is discussed. 
 The natural polyglutamate folate was discovered by 
Lucy Wills  [8] 80 years ago and she recommended using 
the term vitamin 11 as a ‘twin’ of vitamin B 12 . Later the 
monoglutamate form of this vitamin was synthesized  [9] . 
Humans cannot produce folate. The major dietary sourc-
es of folates are fresh and frozen green leafy vegetables, 
citrus fruits and juices, liver, wheat bread, and legumes 
such as beans. Thus the requirement of this water-soluble 
vitamin is supplied partly by dietary intakes of folates 
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and partly by the use of synthetic folic acid, and to esti-
mate doses we have to add these two forms of this vita-
min.
 After dietary intake of polyglutamate folates and the 
intended supply of synthetic monoglutamate folic acid, 
these undergo absorption in the cells of the upper small 
intestine ( fig. 1 ). Folic acid can absorb directly, while fo-
late is changed into the monoglutamate form by conju-
gase enzymes. In the next step these monoglutamates are 
converted to dihydrofolate and then to tetrahydrofolate 
(THF) by reductase enzymes. THF is the parent com-
pound of all biologically active forms of this vitamin. 
THF is converted to 5,10-methylene-THF and 5-methy-
lene-THF (5-MTHF) before transfer into the hepatic por-
tal vein which then leads to the liver and onwards to the 
systemic blood circulation and all body tissues.
 When meat, fish, or plant proteins are digested, amino 
acids, e.g. methionine, are released, and methionine is 
converted to homocysteine. Homocysteine is a toxic me-
tabolite; therefore, humans neutralize it normally as soon 
as possible. On the one hand, homocysteine is metabo-
lized via the transsulfuration pathway to form cystathio-
nine catalyzed by cystathionine   -synthase and serine 
hydroxymethyltransferase. Cystathionine   -synthase re-
quires pyridoxal 5  -phosphate, i.e. vitamin B 6 , as a cofac-
tor. On the other hand, remethylation of homocysteine to 
methionine is catalyzed by methionine synthase. This 
enzyme requires vitamin B 12 as a cofactor and 5-MTHF 
as the methyl donor. The latter explains the importance 
of folate-folic acid deficiency in the origin of NTD.
 The most important cause of hyperhomocysteinemia 
and/or a lack of methionine is the polymorphism of the 
MTHF-reductase (MTHFR) gene. The MTHFR:c.677C 1 T 
mutation has been identified and it results in a thermo-
labile variant (Ala225Val) of the MTHFR enzyme with
a 40% reduction in its activity of CT (heterozygote) and 
with very low (about 70% reduction) activity of the TT 
(homozygote) forms. Vitamin B 2 is a cofactor of the 
MTHRF enzyme. The enzyme variants due to its mutant 
gene pairs cannot effectively catalyze the pathway of 
Vitamin B11
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(monoglutamate)
Cystathionase
B6
Monoglutamate
Reductase
Dihydrofolate
Reductase
Tetrahydrofolate
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5-methyl-THF
Methylene-THF-
reductase
B2
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 Fig. 1. Metabolism of homocysteine and the effect of folate-folic acid (vitamin B 11 ), vitamin B 12 , and vitamin B 6 . CH 3 = Methyl group. 
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5,10-methylene-THF to 5-MTHF, i.e. the methyl donor 
for methionine synthase. About 10–12% of the European 
population is homozygous (TT), while about 40% are 
heterozygotes (CT) for this polymorphism of MTHFR 
gene pairs. The frequency of TT and CT genotypes is 11.1 
and 45.2%, respectively, in the Hungarian population  [10] . 
 The lower activity of the MTHFR enzyme reduces the 
production of 5-MTHF and increases the plasma homo-
cysteine level which causes a delay in the closure of the 
neural tube and thus indirectly NTD. If the mother is a 
homozygote for this mutation, the risk of NTD is 2-fold; 
if both the mother and fetus are homozygotes, the risk of 
NTD increases 6- to 7-fold. Heterozygotes have a slight 
increase in the risk of NTD.
 Practical Use of This New Method for the Prevention 
of NTD 
 There are four approaches to using folic acid or appro-
priate multivitamins for women of childbearing age who 
are capable of becoming pregnant.
 Consumption of Folate-Rich and Other Vitamin-Rich 
Diets 
 The usual daily intake of folate is about 0.16–0.20 mg/
day in Hungary and this consumption is not significant-
ly higher in other countries. Thus, it is difficult to imag-
ine about a 3.5-fold increase in folate intake every day in 
anticipation of conception, which would require the con-
sumption of 500 g raw spinach, 900 g boiled spinach, or 
900 g raw broccoli, i.e. about 15 servings of broccoli each 
day. Furthermore, some part of dietary folate is lost 
through cooking and processing. Finally, an extreme in-
crease in the consumption of extra folate from natural 
food is relatively ineffective at increasing the folate status 
 [11] .
 In conclusion, a diet rich in folate is important for the 
prevention of NTD but cannot alone completely neutral-
ize the genetic predisposition for this CA.
 Periconceptional Supplementation 
 Substantial evidence is available to advise all women 
capable of becoming pregnant to have periconceptional 
(i.e. 2–3 months before and until 3 months after concep-
tion) folic acid or folic acid-containing multivitamin sup-
plementation to reduce the occurrence of NTD.
 Thus periconceptional use of folic acid or multivita-
mins would be a simple and useful approach. Neverthe-
less, this opportunity is missed frequently.
 The major problem is that about 50% of pregnancies 
are unplanned in the USA, Hungary, and many other
industrialized countries. 
 If women have unplanned pregnancies and are not us-
ing a supplement routinely, they cannot take advantage 
of this new preventive method during the preconception-
al period. The explanation is clear: at the time of the first 
missed menstrual period and on about the 15th postcon-
ceptional day, when the possible pregnancy is recognized, 
the neural tube is preparing to close. 
 There are two public health tasks to help prospective 
pregnant women in order to increase their use of pericon-
ceptional folic acid or multivitamins. The first is a strong 
and widespread educational campaign to suggest the 
start of use of folic acid or multivitamins immediately 
after discontinuation of oral contraceptive pills or other 
contraceptive methods when couples decide to have a 
baby. However, unfortunately these campaigns have had 
only limited success in all countries  [12] . 
 The second important task is to establish a network of 
pre- or periconceptional care within the primary health 
care. The HPS was launched in 1984  [4] and the Hungar-
ian RCT and CCT – presented previously – were based on 
the HPS. We prefer to use the term periconception in-
stead of the usual preconception because prenatal care 
usually begins in about the 7th to 12th week of pregnan-
cy, but the most sensitive and vulnerable time of fetal de-
velopment is from the 3rd postconceptional week until 
the 8th week, i.e. between the 5th and 10th gestational 
weeks, and this period is omitted from medical health 
services; thus embryos are uncared for and, in general, 
unprotected. Pre-/periconceptional care is an optimal in-
frastructure for the launch of preconceptional folic acid 
or multivitamin supplementation.
 The Dose of Folic Acid 
 Based upon the Hungarian RCT and some observa-
tional studies, experts in the USA recommended that ‘all 
women of childbearing age who are capable of becoming 
pregnant should consume 0.4 mg of folic acid per day for 
the purpose of reducing their risk of having a pregnan-
cy affected by spina bifida or other NTD’  [13] , and this 
recommendation was subsequently followed by several 
countries. However, there was no scientific evidence for 
the efficacy of this dose in 1992. McPartlin et al.  [14] sug-
gested that the optimal daily intake of folate/folic acid for 
the prevention of NTD in the periconceptional period is 
about 0.66 mg/day. Daily et al.  [15] demonstrated that 
the lowest risk of having a child with NTD was related to 
a red blood cell folate concentration of 906 nmol/l or 
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more. However, it was not reached within 4 weeks after 
the previously recommended 0.4 mg folic acid supple-
mentation; practically 8–12 weeks are needed to reach the 
recommended level of 906 nmol/l, while the use of 0.8 mg 
folic acid resulted in the necessary red blood cell folate 
concentration at 4.2  8 3.5 weeks  [16, 17] .
 In our opinion, 1.0 mg of folate/folic acid daily seems 
to be optimal for all prepregnant and pregnant women, 
via the consumption of 0.2–0.3 mg folate through diet 
and via supplementation with 0.7–0.8 mg folic acid.
 A Further Dilemma Is the Choice between Folic Acid 
and Multivitamins 
 The use of multivitamins containing folic acid and 
other B vitamins in the Hungarian RCT  [5] and CCT  [6] 
and in the study by Smithells et al.  [1] showed a higher 
efficacy (about 90%) in the reduction of NTD than the 
MRC Vitamin Study  [3]  using a high dose of folic acid 
alone (71%) and the Chinese-US study  [7] using a low 
dose of folic acid (41–79%). The usual argument against 
the use of other vitamins is that the supplementation 
group of ‘other vitamins’ in the MRC Vitamin Study  [3] 
did not result in a significant reduction in recurrent NTD. 
However, it is worth mentioning that there was a 40% re-
duction (2.6 vs. 4.3%) in recurrent NTD near to the level 
of significance after supplementation with other vita-
mins. 
 Another argument for the use of folic acid-containing 
multivitamins is that this supplementation is effective for 
the reduction of some others CAs, but there are very lim-
ited data concerning a similar preventive effect of folic 
acid alone for these CAs.
 Finally, hyperhomocysteinemia plays a role in the ori-
gin of at least some part of NTD, and vitamins B 12 , B 2 , 
and B 6 are important cofactors in the folate-homocyste-
ine metabolism ( fig. 1 ).
 Obviously, folate/folic acid is a key factor in homocys-
teine detoxication, but vitamins B 12 , B 2 , and B 6 also have 
a role in this biological mechanism and it may explain a 
higher efficacy of a multivitamin including these 4 ‘fetal 
protective’ B vitamins as folic acid alone in the reduction 
of NDT.
 In conclusion, folic acid-containing multivitamins 
seem to be more effective in the prevention of NTD, 
though obviously the use of folic acid alone is more simple 
and cheaper.
 The Last Recent Dilemma: Folic Acid or Methylfolate 
 After their intake, both natural folate and synthetic 
folic acid are converted to 5-MTHF and this is the pre-
dominant folate form usually found in blood plasma. In 
recent years, a nature-identical folate of 5-MTHF as 6S-
5-MTHF has been synthesized as a calcium salt and mar-
keted as Metafolin   [18] . Thus it is a synthetic product but 
is equal to its natural form; therefore, the term folate is 
correct.
 At present, the use of 6S-5-MTHF seems to be better 
than the use of folic acid in four aspects:
 (i) The previously mentioned polymorphism of 
MTHFR:c.677C 1 T in folate metabolism is associated 
with an increased risk of NTD, but, in contrast to folic 
acid, the plasma response of 6S-5-MTHF is not affected 
in women carrying the common MTHFR:c.677C 1 T 
variant  [19] .
 (ii) The previous major concern regarding the use of 
folic acid, mainly in higher doses, was its possible mask-
ing effect in patients with pernicious anemia. A low con-
centration of B 12 may compromise the activity of methio-
nine synthase (which can reconvert homocysteine back 
to methionine as a form of ‘detoxication’); thus cells suf-
fer a pseudo-folate deficiency that suppresses DNA bio-
synthesis, which results in the clinical signs and symp-
toms of megaloblastic anemia. Folic acid bypasses this 
‘trap’ because it can be reduced directly to THF, which 
can then be cycled to the folate forms used in DNA bio-
synthesis. This treats the anemia but still allows plasma 
homocysteine concentrations to rise and continue the in-
terruption to methylation reactions with the possible sec-
ondary outcome of demyelination of nerves, resulting in 
neuropathy. By contrast, supplementation with 6S-5-
MTHF is not ‘trapped’, i.e. not recycled to THF, and 
therefore cannot ‘mask’ the clinical signs and symptoms 
of anemia and thus B 12 deficiency is more likely to be di-
agnosed and treated  [18] .
 (iii) 6S-5-MTHF may be associated with a reduced in-
teraction with antifolate drugs that inhibit dihydrofolate 
reductase  [20] .
 (iv) 6S-5-MTHF and folic acid showed comparable 
physiological activity, bioavailability, and absorption 
 [16] . Thus the equimolar dose of 6S-5-MTHF appears  to
be at least as effective as folic acid in increasing maternal 
red blood cell folate concentrations in women of child-
bearing age  [21, 16] .
 On the other hand, human data of controlled epide-
miological studies regarding the preventive effect of 6S-
5-MTHF for NTD are not available.
 Food Fortification 
 Food fortification seems to be the most practical 
means of supplementation with folic acid and other vita-
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mins for women with unplanned pregnancies. This pub-
lic health initiative is comparable to the prevention of goi-
ter by the addition of iodine to salt.
 In February 1996, the US Department of Health and 
Human Services ordered food fortification with folic acid 
of all cereal grain products at a level of 0.14 mg/100 g be-
ginning January 1998. This adds only about 0.1 mg folic 
acid to the average daily diet of women of reproductive 
age; nevertheless, there was a 26% reduction in the total 
(birth + fetal) prevalence of NTD  [22] . The estimated 
benefit-cost ratio of US folic acid fortification is 40: 1  [23] ; 
thus the estimated economic benefit in US dollars is 
312–425 millions annually. Canada also introduced a 
mandatory flour fortification with folic acid (0.15 mg/
100 g of white flour) in September 1998 and a 42% reduc-
tion was found in the total prevalence of NTD  [24] . Later 
many other countries introduced mandatory flour forti-
fication and, as far as we know, at present this public 
health project exists in 57 countries. However, manda-
tory flour or other food fortification with folic acid is not 
available in European countries.
 Mandatory flour fortification would be especially im-
portant for the large proportion of women with lower lev-
els of education and income who, in general, have diffi-
culty buying more expensive foods rich in folate and oth-
er vitamins and who more frequently have unplanned 
pregnancies. 
 Our major concern regarding this approach is the low 
dose of folic acid and the lack of vitamin B 12 . On the one 
hand, there is a well-known dose-effect relation in the 
preventive effect of folic acid for NTD, and it explains that 
some experts recommend the use of 5 mg folic acid  [25] . 
In our opinion, 0.8 mg is a good compromise. On the 
other hand, vitamin B 12 is an independent risk factor in 
the origin of NTD, and the combination of folic acid and 
vitamin B 12 can prevent the so-called ‘masking effect’ of 
folic acid in patients with pernicious anemia.
 However, there are two other opposite opinions regard-
ing flour fortification with folic acid. Results of studies 
showed that folate deficiency is a precancerous state, but 
recent data suggested a possible carcinogenic effect of high 
doses of folic acid as well. Thus there may be a U-shaped 
risk of cancer connected with the doses of folic acid  [26] . 
Some experts therefore did not recommend the introduc-
tion of flour fortification by folic acid because it may be 
associated with risk in older people with precancerous le-
sions, e.g. in the colon. The opposite opinion is based on 
the good experiences with flour fortification in the USA 
and Canada; thus Oakley  [27] declared that inertia in folic 
acid fortification is a public health malpractice.
 Combination of Oral Contraceptives and Folate 
 Periconceptional folic acid or folic acid-containing 
multivitamin supplementation requires planned concep-
tion, and the proportion of females who prepare for con-
ception is between only 30 and 75% in different countries.
 The combination of oral contraceptive pills with folate 
is another option  [28] . Recently, the US FDA (Food and 
Drug Administration) approved a new medicinal prod-
uct comprised of drospirenone and ethinyl estradiol as 
contraceptive components and levomefolate calcium as a 
folate component. 
 Four advantages can be expected from this new ap-
proach:
 (i) Overall, 30–50% of women between the ages of 15 
and 49 years take oral contraceptives in most Western 
European countries  [29] . Information on the beneficial 
effects of folic acid or folic acid containing multivitamins 
could and should be provided on the contraceptive pack-
et. Thus our hope is that the user of this medicinal prod-
uct will have better knowledge to understand that the 
start of the use of folic acid or multivitamins immedi-
ately after the discontinuation of oral contraceptive pills 
is necessary when couples decide to have a baby.
 (ii) It is a well-known fact that the compliance of pill 
use is not prefect, e.g. only 42% of oral contraceptive us-
ers remembered to take their pill every day  [30] . Thus 
inadvertent ‘accidental’ conception may occur in about 
2% of women who use contraceptive pills; the parallel use 
of folate is important for the prevention of NTD in their 
fetuses.
 (iii) Studies showed that 42% of women who discon-
tinued pill use did not consult with their health care pro-
vider  [31] . In addition, about 60% of young females who 
used oral contraceptives and stopped in order to have 
their first pregnancy had no connection with gynecolo-
gists in Hungary  [4] .
 (iv) The European Active Surveillance Study (EURAS) 
evaluated 2,000 women who stopped taking oral contra-
ceptives in order to become pregnant  [32] , and 31% were 
pregnant within the first month after stopping oral con-
traceptive use and 46% after 3 months. In another study, 
conception occurred within 2 months after the cessation 
of oral contraceptive use in 30–40% of all pregnancies 
and within 4 months in 50–60%  [33] . Thus an important 
benefit is that women who discontinued the use of a com-
bination of contraceptive pills and folate have a higher 
blood folate level – albeit, of course, with a decline paral-
lel with time. This ‘post-use effect’ may be useful to re-
duce the risk of NTD. 
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 However, while the plasma folate level reflects the in-
take of folate/folic acid in previous days, the red blood cell 
folate level shows a more constant, characteristic level be-
cause its change is slow within the 120-day life of eryth-
rocytes. Thus it is understandable that the plasma folate 
concentration has a faster decrease after the discontinu-
ation of oral contraceptives, and it is important to know 
that the cells of the fetus are exposed to circulating plas-
ma folate.
 In conclusion, the expected benefits of combined oral 
contraceptives with folate can be defined, while it is dif-
ficult to estimate the possible unexpected risks; thus the 
introduction of this new medicinal product for the pre-
vention of NTD in the most important target group, 
women of reproductive age, seems to be promising.
 Food fortification with folic acid and the combina-
tion of oral contraceptives with folate would be impor-
tant because the beneficial effect of periconceptional
folic acid/multivitamin supplementation has not been 
used widely and appropriately for the prevention of 
NTD in medical practice. In addition, there was signif-
icant improvement in the prenatal diagnosis of fetuses 
affected with NTD.
 Prenatal Diagnosis of Fetuses Affected with NTD 
 Before the 1960s nearly all victims of NTD had fatal 
outcomes. In the 1960s physicians introduced very early 
complex surgical and medical interventions and the lives 
of victims were saved in the majority of spina bifida cases 
(of course, anencephaly has remained lethal). In the 1970s 
the selective criteria of surgical intervention in cases with 
spina bifida was introduced to reduce the production of 
multiply handicapped children. 
 In the 1980s prenatal screening based on maternal se-
rum   -fetoprotein (MS-AFP) was introduced for the de-
tection of NTD in fetuses. In low-risk populations the 
detection rate (i.e. sensitivity) of MS-AFP testing for open 
NTD varies from 72 to 91% and the specificity from 96.2 
to 98.7%  [34] . Since the early 1990s there has been great 
progress in the efficacy of ultrasound diagnosis in the 
detection of NTD in fetuses. However, overall only 10–
40% of all spina bifida cases are picked up during routine 
screening and even anencephaly may be missed in first 
trimester scans  [28] . However, all anencephalic fetuses 
are diagnosed by ultrasound in the second trimester, and 
about 80% of fetuses affected with spina bifida are also 
diagnosed on the basis of the so-called ‘lemon’ and ‘ba-
nana’ signs which are characteristic changes in the head 
of affected fetuses. Mainly the diagnosis of fetuses with 
closed spina bifida is missed. 
 After the prenatal diagnosis of NTD, informed preg-
nant women have to choose between two evils: continu-
ing their pregnancy with the long-term medical, psycho-
logical, and financial consequences of their multiply 
handicapped children or deciding to terminate their 
pregnancy at about the end of the second trimester, when 
their moving fetuses are expected very much. Our study 
showed that 99% of pregnant women with anencephalic 
fetuses and 97% of women who had diagnosed fetuses 
with spina bifida decided to terminate their pregnancy.
 Finally, since the late 1990s, we have had a chance to 
reduce the maldevelopment of the neural tube due to in-
tentional modification (supplementation) of the diet by 
folic acid or folic acid-containing multivitamins in the 
periconceptional period of life.
 Previously, we estimated the proportion of pregnant 
women with folic acid/multivitamin supplementation 
between 1980 and 1996  [35] . The rate of folic acid/multi-
vitamin supplementation use was 52.4% after the first 
visit to a prenatal care clinic, but the estimated propor-
tion of women with preconceptional folic acid/multivita-
min supplementation was only 12%. Nevertheless, there 
was a robust drop in the total prevalence of recorded cas-
es with NTD in the Hungarian Congenital Abnormality 
Registry because 76.9% of cases with NTD were found in 
the group of elective termination of pregnancy after their 
prenatal diagnosis and only about 5% of NTD cases were 
prevented by periconceptional folic acid/multivitamin 
supplementation in 2008  [36] .
 At present, periconceptional folic acid or folic acid-
containing multivitamin supplementation as a preven-
tive method against NTD offers an optimal medical al-
ternative compared with elective termination of NTD fe-
tuses for the following reasons: 
 (i) The efficacy of these two methods is nearly the 
same: folic acid can prevent about 70% of NTD concep-
tions while folic acid-containing multivitamin can pre-
vent about 90%, and the diagnostic efficacy of ultrasound 
is nearly 100% in anencephalic fetuses and about 80% in 
fetuses with different manifestations of spina bifida.
 (ii) The cost of multivitamins and particularly folic 
acid is much lower than that of prenatal diagnosis of an 
NTD fetus followed by elective termination of the preg-
nancy.
 (iii) The risks of folic acid/multivitamin use are min-
imal, while the early complications and late adverse
consequences of pregnancy terminations cannot be ne-
glected.
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 (iv) Elective termination of pregnancy due to NTD fe-
tuses between the 16th and 20th gestation weeks induces 
serious psychological crises in many pregnant women. 
Similar problems do not occur in pregnant women with 
folic acid/multivitamin use.
 (v) Termination of pregnancy due to NTD fetuses as-
sociates with a moral dilemma in several people includ-
ing females and medical doctors. In contrast, the birth of 
a healthy baby after periconceptional folic acid/multivi-
tamin supplementation results in great happiness and 
improved self-esteem  [4] . 
 Conclusion 
 Obviously, prevention of NTD is much better than 
elective termination of a pregnancy after the prenatal di-
agnosis of NTD; thus we have to do our best to change the 
present trends. This review paper wants to promote this 
activity confirmed by the truth of the old English prov-
erb: ‘An ounce of prevention is better than a pound of 
care’. However, it is necessary to educate prospective par-
ents on the appropriate use of periconceptional folic acid/
multivitamin supplementation [0.8 mg folic acid instead 
of the previously recommended 0.4 mg folic acid or using 
the most effective folic acid (0.8 mg)-containing multivi-
tamins] to prevent NTD in medical practice.
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